Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01703754 · ClinicalTrials.gov registry record · Phase 2
Adenoviral Vector Monotherapy or Combination With Chemotherapy in Subjects With Recurrent/Metastatic Breast Cancer.
A Phase 2 study, sponsored by Alaunos Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT01703754 is a Phase 2 study that was terminated before completion, run by Alaunos Therapeutics. The registered enrollment target is 12 participants.
The verdict
NCT01703754, a Phase 2 study, was terminated before completion, sponsored by Alaunos Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
Phase II, randomized, safety and efficacy study in recurrent/metastatic breast cancer with accessible lesions. Primary End point is rate of Progression Free Survival (PFS) at the 16 week treatment time point. Hypothesis: Adenoviral vector (Ad-RTS-hIL-12) alone and in combination with chemotherapy (palifosfamide) is safe and efficacious.
Interventions
- GENETIC Ad-RTS-hIL-12 and Veledimex
- DRUG Palifosfamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2013-04-04 |
| Est. Completion | 2014-08-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01703754
The ClinicalTrials.gov registry entry for NCT01703754 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alaunos Therapeutics, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ad-RTS-hIL-12 and Veledimex is the first listed.
NCT01703754 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01703754 about?
NCT01703754 is a clinical study titled "Adenoviral Vector Monotherapy or Combination With Chemotherapy in Subjects With Recurrent/Metastatic Breast Cancer.". Phase II, randomized, safety and efficacy study in recurrent/metastatic breast cancer with accessible lesions. Primary End point is rate of Progression Free Survival (PFS) at the 16 week treatment time point. Hypothesis: Adenoviral vector (Ad-RTS-hIL-12) alone and in combination with chemotherapy (...
What is the current status of trial NCT01703754?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2013-04-04. Estimated completion is 2014-08-07.
What interventions are being tested in trial NCT01703754?
The interventions under investigation include: Ad-RTS-hIL-12 and Veledimex (GENETIC), Palifosfamide (DRUG).
Who is sponsoring clinical trial NCT01703754?
This trial is sponsored by Alaunos Therapeutics, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.